Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1633–1640. doi: 10.1038/sj.bjc.6690261

Making the most of rodent tumour systems in cancer drug discovery

M C Bibby 1
PMCID: PMC2362798  PMID: 10206270

Full Text

The Full Text of this article is available as a PDF (314.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998 Jan 16;279(5349):377–380. doi: 10.1126/science.279.5349.377. [DOI] [PubMed] [Google Scholar]
  2. Atwell G. J., Rewcastle G. W., Baguley B. C., Denny W. A. Synthesis and anti-tumour activity of topologically-related analogues of flavoneacetic acid. Anticancer Drug Des. 1989 Aug;4(2):161–169. [PubMed] [Google Scholar]
  3. Baillie C. T., Winslet M. C., Bradley N. J. Tumour vasculature--a potential therapeutic target. Br J Cancer. 1995 Aug;72(2):257–267. doi: 10.1038/bjc.1995.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bibby M. C., Double J. A. Flavone acetic acid--from laboratory to clinic and back. Anticancer Drugs. 1993 Feb;4(1):3–17. doi: 10.1097/00001813-199302000-00001. [DOI] [PubMed] [Google Scholar]
  5. Bibby M. C., Double J. A., Wahed I. A., Hirbawi N., Baker T. G. The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide. Br J Cancer. 1988 Aug;58(2):139–143. doi: 10.1038/bjc.1988.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bibby M. C. Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment? Br J Cancer. 1991 Jan;63(1):3–5. doi: 10.1038/bjc.1991.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bibby M. C., Sleigh N. R., Loadman P. M., Double J. A. Potentiation of EO9 anti-tumour activity by hydralazine. Eur J Cancer. 1993;29A(7):1033–1035. doi: 10.1016/s0959-8049(05)80218-7. [DOI] [PubMed] [Google Scholar]
  8. Bresalier R. S., Hujanen E. S., Raper S. E., Roll F. J., Itzkowitz S. H., Martin G. R., Kim Y. S. An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res. 1987 Mar 1;47(5):1398–1406. [PubMed] [Google Scholar]
  9. Chan R. C., Babbs C. F., Vetter R. J., Lamar C. H. Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst. 1984 Jan;72(1):145–150. doi: 10.1093/jnci/72.1.145. [DOI] [PubMed] [Google Scholar]
  10. Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
  11. Chaplin D. J., Pettit G. R., Parkins C. S., Hill S. A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl. 1996 Jul;27:S86–S88. [PMC free article] [PubMed] [Google Scholar]
  12. Ching L. M., Joseph W. R., Baguley B. C. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer. 1992 Jul;66(1):128–130. doi: 10.1038/bjc.1992.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Collard J., Matthew A. M., Double J. A., Bibby M. C. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer. 1995 Jun;71(6):1199–1203. doi: 10.1038/bjc.1995.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Corbett T. H., Valeriote F. A., Baker L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs. 1987;5(1):3–20. doi: 10.1007/BF00217664. [DOI] [PubMed] [Google Scholar]
  15. Cowen S. E., Bibby M. C., Double J. A. Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol. 1995;34(3):357–360. doi: 10.3109/02841869509093989. [DOI] [PubMed] [Google Scholar]
  16. Dark G. G., Hill S. A., Prise V. E., Tozer G. M., Pettit G. R., Chaplin D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997 May 15;57(10):1829–1834. [PubMed] [Google Scholar]
  17. Dong Z., Radinsky R., Fan D., Tsan R., Bucana C. D., Wilmanns C., Fidler I. J. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst. 1994 Jun 15;86(12):913–920. doi: 10.1093/jnci/86.12.913. [DOI] [PubMed] [Google Scholar]
  18. Double J. A., Bibby M. C. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst. 1989 Jul 5;81(13):988–994. doi: 10.1093/jnci/81.13.988. [DOI] [PubMed] [Google Scholar]
  19. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 1992 Jun;3(3):175–210. doi: 10.1097/00001813-199206000-00001. [DOI] [PubMed] [Google Scholar]
  20. Eijdems E. W., de Haas M., Timmerman A. J., Van der Schans G. P., Kamst E., de Nooij J., Astaldi Ricotti G. C., Borst P., Baas F. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer. 1995 Jan;71(1):40–47. doi: 10.1038/bjc.1995.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Fidler I. J., Naito S., Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev. 1990 Sep;9(2):149–165. doi: 10.1007/BF00046341. [DOI] [PubMed] [Google Scholar]
  22. Fidler I. J. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. 1991 Oct;10(3):229–243. doi: 10.1007/BF00050794. [DOI] [PubMed] [Google Scholar]
  23. Fidler I. J., Wilmanns C., Staroselsky A., Radinsky R., Dong Z., Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 1994 Jun;13(2):209–222. doi: 10.1007/BF00689637. [DOI] [PubMed] [Google Scholar]
  24. Field S. B., Needham S., Burney I. A., Maxwell R. J., Coggle J. E., Griffiths J. R. Differences in vascular response between primary and transplanted tumours. Br J Cancer. 1991 May;63(5):723–726. doi: 10.1038/bjc.1991.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Fitzsimmons S. A., Workman P., Grever M., Paull K., Camalier R., Lewis A. D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996 Mar 6;88(5):259–269. doi: 10.1093/jnci/88.5.259. [DOI] [PubMed] [Google Scholar]
  26. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  27. Fu X. Y., Besterman J. M., Monosov A., Hoffman R. M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345–9349. doi: 10.1073/pnas.88.20.9345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. GOLDIN A., HUMPHREYS S. R., MANTEL N., VENDITTI J. M. Modification of treatment of schedules in the management of advanced mouse leukemia with amethopterin. J Natl Cancer Inst. 1956 Aug;17(2):203–212. [PubMed] [Google Scholar]
  29. GOLDIN A., MANTEL N. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. Cancer Res. 1957 Aug;17(7):635–654. [PubMed] [Google Scholar]
  30. Goldrosen M. H., Paolini N., Jr, Holyoke E. D. Description of a murine model of experimental hepatic metastases. J Natl Cancer Inst. 1986 Sep;77(3):823–828. doi: 10.1093/jnci/77.3.823. [DOI] [PubMed] [Google Scholar]
  31. Gutman M., Fidler I. J. Biology of human colon cancer metastasis. World J Surg. 1995 Mar-Apr;19(2):226–234. doi: 10.1007/BF00308631. [DOI] [PubMed] [Google Scholar]
  32. Hill S. A., Lonergan S. J., Denekamp J., Chaplin D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer. 1993;29A(9):1320–1324. doi: 10.1016/0959-8049(93)90082-q. [DOI] [PubMed] [Google Scholar]
  33. Jirtle R. L. Chemical modification of tumour blood flow. Int J Hyperthermia. 1988 Jul-Aug;4(4):355–371. doi: 10.3109/02656738809016490. [DOI] [PubMed] [Google Scholar]
  34. Kong H. L., Crystal R. G. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst. 1998 Feb 18;90(4):273–286. doi: 10.1093/jnci/90.4.273. [DOI] [PubMed] [Google Scholar]
  35. Laws A. L., Matthew A. M., Double J. A., Bibby M. C. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995 Jun;71(6):1204–1209. doi: 10.1038/bjc.1995.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Martin D. S., Stolfi R. L., Sawyer R. C. Commentary on "clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep. 1984 Nov;68(11):1317–1318. [PubMed] [Google Scholar]
  37. Martin D. S. The scientific basis for adjuvant chemotherapy. Cancer Treat Rev. 1981 Sep;8(3):169–189. doi: 10.1016/s0305-7372(81)80015-1. [DOI] [PubMed] [Google Scholar]
  38. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986 Dec;46(12 Pt 1):6387–6392. [PubMed] [Google Scholar]
  39. McGown A. T., Fox B. W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des. 1989 Mar;3(4):249–254. [PubMed] [Google Scholar]
  40. Morikawa K., Walker S. M., Nakajima M., Pathak S., Jessup J. M., Fidler I. J. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 1988 Dec 1;48(23):6863–6871. [PubMed] [Google Scholar]
  41. Muggia F. M. Closing the loop: providing feedback on drug development. Cancer Treat Rep. 1987 Jan;71(1):1–2. [PubMed] [Google Scholar]
  42. Newlands E. S., Stevens M. F., Wedge S. R., Wheelhouse R. T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997 Jan;23(1):35–61. doi: 10.1016/s0305-7372(97)90019-0. [DOI] [PubMed] [Google Scholar]
  43. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996 Mar 28;380(6572):364–366. doi: 10.1038/380364a0. [DOI] [PubMed] [Google Scholar]
  44. Pettit G. R., Singh S. B., Hamel E., Lin C. M., Alberts D. S., Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989 Feb 15;45(2):209–211. doi: 10.1007/BF01954881. [DOI] [PubMed] [Google Scholar]
  45. Pettit G. R., Temple C., Jr, Narayanan V. L., Varma R., Simpson M. J., Boyd M. R., Rener G. A., Bansal N. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 1995 Jun;10(4):299–309. [PubMed] [Google Scholar]
  46. Pluda J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol. 1997 Apr;24(2):203–218. [PubMed] [Google Scholar]
  47. Quinn P. K., Bibby M. C., Cox J. A., Crawford S. M. The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer. 1992 Aug;66(2):323–330. doi: 10.1038/bjc.1992.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rewcastle G. W., Atwell G. J., Baguley B. C., Boyd M., Thomsen L. L., Zhuang L., Denny W. A. Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem. 1991 Sep;34(9):2864–2870. doi: 10.1021/jm00113a027. [DOI] [PubMed] [Google Scholar]
  49. Rewcastle G. W., Atwell G. J., Baguley B. C., Calveley S. B., Denny W. A. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem. 1989 Apr;32(4):793–799. doi: 10.1021/jm00124a012. [DOI] [PubMed] [Google Scholar]
  50. Rewcastle G. W., Atwell G. J., Li Z. A., Baguley B. C., Denny W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem. 1991 Jan;34(1):217–222. doi: 10.1021/jm00105a034. [DOI] [PubMed] [Google Scholar]
  51. Rewcastle G. W., Atwell G. J., Palmer B. D., Boyd P. D., Baguley B. C., Denny W. A. Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J Med Chem. 1991 Feb;34(2):491–496. doi: 10.1021/jm00106a003. [DOI] [PubMed] [Google Scholar]
  52. Robertson N., Stratford I. J., Houlbrook S., Carmichael J., Adams G. E. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol. 1992 Aug 4;44(3):409–412. doi: 10.1016/0006-2952(92)90429-m. [DOI] [PubMed] [Google Scholar]
  53. Rowell N. P., Flower M. A., McCready V. R., Cronin B., Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol. 1990 Aug;18(4):283–292. doi: 10.1016/0167-8140(90)90108-9. [DOI] [PubMed] [Google Scholar]
  54. SKIPPER H. E., SCHABEL F. M., Jr, BELL M., THOMSON J. R., JOHNSON S. On the curability of experimental neoplasms. I. Amethopterin and mouse leukemias. Cancer Res. 1957 Aug;17(7):717–726. [PubMed] [Google Scholar]
  55. SKIPPER H. E., SCHABEL F. M., Jr, WILCOX W. S. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep. 1964 Feb;35:1–111. [PubMed] [Google Scholar]
  56. Segura-Aguilar J., Cremades A., Llombart-Bosch A., Monsalve E., Ernster L., Romero F. J. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. Carcinogenesis. 1994 Aug;15(8):1631–1636. doi: 10.1093/carcin/15.8.1631. [DOI] [PubMed] [Google Scholar]
  57. Smitskamp-Wilms E., Peters G. J., Pinedo H. M., van Ark-Otte J., Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol. 1994 Apr 20;47(8):1325–1332. doi: 10.1016/0006-2952(94)90330-1. [DOI] [PubMed] [Google Scholar]
  58. Stevens M. F., Hickman J. A., Stone R., Gibson N. W., Baig G. U., Lunt E., Newton C. G. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem. 1984 Feb;27(2):196–201. doi: 10.1021/jm00368a016. [DOI] [PubMed] [Google Scholar]
  59. Stolfi R. L., Stolfi L. M., Sawyer R. C., Martin D. S. Chemotherapeutic evaluation using clinical criteria in spontaneous, autochthonous murine breast tumors. J Natl Cancer Inst. 1988 Mar 2;80(1):52–55. doi: 10.1093/jnci/80.1.52. [DOI] [PubMed] [Google Scholar]
  60. Stratford I. J., Adams G. E., Godden J., Nolan J., Howells N., Timpson N. Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer. 1988 Aug;58(2):122–127. doi: 10.1038/bjc.1988.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Tan M. H., Holyoke E. D., Goldrosen M. H. Murine colon adenocarcinoma: syngeneic orthotopic transplantation and subsequent hepatic metastases. J Natl Cancer Inst. 1977 Nov;59(5):1537–1544. doi: 10.1093/jnci/59.5.1537. [DOI] [PubMed] [Google Scholar]
  62. Warren R. S., Yuan H., Matli M. R., Gillett N. A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995 Apr;95(4):1789–1797. doi: 10.1172/JCI117857. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES